Objective: To investigate the clinical characteristics and prognosis of hematopathy patients with chromosome 3 abnormality.
Methods: The clinical data of the 125 hematopathy patients with chromosome 3 abnormality in our hospital from January 2011 to June 2018 were retrospectively analyzed. The conventional karyotype analysis was performed by R-banding. According to the main genetic abnormalities, the patients were divided into 3 group: group with 3q abnormality, 3p abnormality and +3/-3.
Results: Among 3 kinds of gene abnormality 3q abnormality was the most common one, followed by +3 and 3p abnormality. No significant differences were found in age, sex, WBC, Plt count and Hb level all in each group (P＞0.05). Among the 125 patients, 42 patients died without treatment or abandoned treatment, and 83 patients received more than 2 courses of treatment. The 2-year overall survival (OS) rate in the three groups was 30.25%, 43.0% and 58.7% respectively. The 2-year OS rate in the 3q abnormal group was significantly lower than that in the +3/-3 group (P=0.041). Among the 3q abnormality, the detection rate of the patients with 3q21/3q26 locus abnormality was the highest, and their 2-year OS rate (41.1%) was higher than that in other 3q locus abnormality (11.1%) (P=0.044).
Conclusion: Hematopathy patients with chromosome 3 abnormality, especially 3q abnormality often show a poor prognosis, however, 3q abnormality involving 3q21/3q26 locus indicates a better prognosis relatively.
题目: 125例伴3号染色体异常血液病患者的临床特征及预后.
目的: 探讨3号染色体异常在血液病患者中的临床特征及其预后的意义.
方法: 回顾分析2011年1月- 2018年6月来于院就诊的125例伴3号染色体异常的血液病患者的临床资料。采用R显带技术进行常规核型分析, 根据主要遗传学异常将患者分为3组：3q异常、3p异常及+3/-3.
结果: 3组中以3q异常最常见, 其次为+3和3p异常。各组在年龄、性别、WBC、Plt计数和Hb水平方面无明显差异（P＞0.05）。125例患者中未治疗即死亡或放弃治疗的42例, 治疗2个疗程以上的共83例；3组患者的2年总生存率分别为30.25%、43.0%和58.7%。3q异常组患者的2年总生存率明显低于+3/-3组（P=0.041）。而3q异常中以涉及3q21/3q26位点异常的检出率最高, 其2年的总生存率(41.1%）明显高于其它的3q位点异常（11.1%）（P=0.044）.
结论: 患者伴有3号染色体异常尤其是3q异常预后较差, 而3q异常中涉及3q21/3q26位点异常的患者预后相对较好.